IL107207A0 - Sustained release pharmaceutical compositions - Google Patents
Sustained release pharmaceutical compositionsInfo
- Publication number
- IL107207A0 IL107207A0 IL107207A IL10720793A IL107207A0 IL 107207 A0 IL107207 A0 IL 107207A0 IL 107207 A IL107207 A IL 107207A IL 10720793 A IL10720793 A IL 10720793A IL 107207 A0 IL107207 A0 IL 107207A0
- Authority
- IL
- Israel
- Prior art keywords
- sustained release
- pharmaceutical compositions
- release pharmaceutical
- gel
- active compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96075292A | 1992-10-14 | 1992-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL107207A0 true IL107207A0 (en) | 1994-01-25 |
Family
ID=25503572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL107207A IL107207A0 (en) | 1992-10-14 | 1993-10-06 | Sustained release pharmaceutical compositions |
Country Status (19)
Country | Link |
---|---|
US (1) | US5863549A (es) |
EP (1) | EP0620740B1 (es) |
JP (1) | JP2613750B2 (es) |
CN (1) | CN1090509A (es) |
AT (1) | ATE180976T1 (es) |
AU (1) | AU672441B2 (es) |
CA (1) | CA2125784A1 (es) |
DE (1) | DE69325256T2 (es) |
ES (1) | ES2133413T3 (es) |
IL (1) | IL107207A0 (es) |
IS (1) | IS4083A (es) |
LV (1) | LV10180A (es) |
MX (1) | MX9306239A (es) |
NZ (1) | NZ256413A (es) |
RU (1) | RU94033520A (es) |
SI (1) | SI9300468A (es) |
UY (1) | UY23665A1 (es) |
WO (1) | WO1994008623A1 (es) |
ZA (1) | ZA937459B (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US6379631B1 (en) | 1996-06-28 | 2002-04-30 | Johnson & Johnson Medical, Inc. | Instrument sterilization container formed of a liquid crystal polymer |
US6264902B1 (en) | 1996-06-28 | 2001-07-24 | Johnson & Johnson Medical, Inc. | Instrument sterilization container having an improved latching mechanism |
PL345216A1 (en) * | 1998-06-29 | 2001-12-03 | Pharmaceuticals Applic Asociat | Methods and transdermal compositions for pain relief |
US8052982B2 (en) | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
AU755443C (en) * | 1998-07-20 | 2006-08-17 | Virbac (Australia) Pty Limited | Bioimplant formulation |
CN1243543C (zh) | 1998-07-20 | 2006-03-01 | 派普泰克有限公司 | 生物植入物配方 |
EP1064934A1 (en) * | 1999-06-30 | 2001-01-03 | Applied Research Systems ARS Holding N.V. | GRF-containing lyophilized pharmaceutical composition |
US6979459B1 (en) | 2000-04-06 | 2005-12-27 | Perricone Nicholas V | Treatment of skin damage using polyenylphosphatidycholine |
US6191121B1 (en) * | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
US6932963B2 (en) | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
US20020106406A1 (en) * | 2000-12-08 | 2002-08-08 | Mchugh Anthony J. | Crystallizable/non-crystallizable polymer composites |
GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
AU2003224649B2 (en) | 2002-03-04 | 2006-09-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Sustained release drug formulations containing a carrier peptide |
KR100906547B1 (ko) | 2002-03-12 | 2009-07-07 | 에띠빠흠 | 생활성 물질의 지속적 전달을 위한 겔화 특성을 갖는 조성물 |
EP1485066B1 (fr) | 2002-03-12 | 2016-09-21 | Ethypharm | Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives |
US20040025791A1 (en) * | 2002-08-09 | 2004-02-12 | Applied Materials, Inc. | Etch chamber with dual frequency biasing sources and a single frequency plasma generating source |
FR2868704B1 (fr) * | 2004-04-07 | 2007-09-14 | Ethypharm Sa | Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires |
EP1765367A4 (en) * | 2004-06-15 | 2010-08-11 | Therapeutics Inc Encore | PHOSPHOLIPID COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE |
US7858115B2 (en) * | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
CA2605000A1 (en) * | 2005-04-25 | 2006-11-02 | Amgen Inc. | Biodegradable peptide sustained release compositions containing porogens |
US7695633B2 (en) * | 2005-10-18 | 2010-04-13 | Applied Materials, Inc. | Independent control of ion density, ion energy distribution and ion dissociation in a plasma reactor |
CU23432B6 (es) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
EP1787658B1 (en) | 2005-11-10 | 2012-03-14 | CHEMI S.p.A. | Sustained release formulations of somatostatin analogue inhibitors of growth hormone |
US8017159B2 (en) * | 2005-11-16 | 2011-09-13 | Idexx Laboratories, Inc. | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same |
US20070245960A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion density |
US20070246163A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with independent capacitive and inductive plasma sources |
US20070245958A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source for controlling ion radial distribution |
US7727413B2 (en) * | 2006-04-24 | 2010-06-01 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source to control plasma ion density |
US20070246161A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with a toroidal plasma source and a VHF capacitively coupled plasma source with variable frequency |
US20070246443A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma process for controlling plasma ion dissociation |
US7780864B2 (en) * | 2006-04-24 | 2010-08-24 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion radial distribution |
US7645357B2 (en) * | 2006-04-24 | 2010-01-12 | Applied Materials, Inc. | Plasma reactor apparatus with a VHF capacitively coupled plasma source of variable frequency |
US20070245961A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source for controlling plasma ion dissociation |
US20070246162A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with an inductive plasma source and a VHF capacitively coupled plasma source with variable frequency |
US7403325B2 (en) * | 2006-05-19 | 2008-07-22 | Xerox Corporation | Electrophoretic display device |
CN106310293A (zh) * | 2007-09-27 | 2017-01-11 | 免疫疫苗技术有限公司 | 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用 |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以GnRH拮抗劑治療攝護腺癌的方法 |
WO2009114959A1 (zh) * | 2008-03-20 | 2009-09-24 | 中国人民解放军军事医学科学院毒物药物研究所 | 可注射用缓释药物制剂及其制备方法 |
JP5715051B2 (ja) * | 2008-06-05 | 2015-05-07 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物 |
RU2536245C2 (ru) * | 2009-05-01 | 2014-12-20 | Ферринг Б.В. | Композиция для лечения рака предстательной железы |
TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
CN102933200B (zh) | 2009-12-18 | 2015-11-25 | 莱迪杜德制药公司 | 包含磷脂的单相凝胶组合物 |
CN103179951B (zh) | 2010-08-20 | 2016-01-20 | 雷迪博士实验室有限公司 | 磷脂储库 |
EP2629779B1 (en) * | 2010-10-22 | 2017-06-21 | Dr. Reddy's Laboratories SA. | Use of storage stable viscous phospholipid depot to treat wounds |
EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
US9260480B2 (en) | 2010-10-27 | 2016-02-16 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
CN103826609A (zh) * | 2011-06-09 | 2014-05-28 | 安米林药品有限责任公司 | 凝胶组合物 |
IN2014CN02581A (es) | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
CA2871820C (en) * | 2012-05-10 | 2020-11-03 | Painreform Ltd. | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof |
US9592266B2 (en) | 2012-06-01 | 2017-03-14 | Ferring B.V. | Manufacture of degarelix |
KR102227966B1 (ko) * | 2019-06-26 | 2021-03-16 | 주식회사 엠이티라이프사이언스 | 비활성 폴리펩타이드 trp의 약제학적 제형 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377567A (en) * | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
US4252793A (en) * | 1979-06-18 | 1981-02-24 | American Lecithin Company | Injectable lecithin preparation |
US4297353A (en) * | 1980-08-04 | 1981-10-27 | Sandoz, Inc. | Non-irritating injectable dosage forms |
US4578391A (en) * | 1982-01-20 | 1986-03-25 | Yamanouchi Pharmaceutical Co., Ltd. | Oily compositions of antitumor drugs |
FR2562421B1 (fr) * | 1984-04-09 | 1989-02-17 | Sandoz Sa | Perfectionnements a la therapie par l'interleukine |
US4761288A (en) * | 1984-09-24 | 1988-08-02 | Mezei Associates Limited | Multiphase liposomal drug delivery system |
GB8603621D0 (en) * | 1986-02-14 | 1986-03-19 | Habib N | Modifying lipid structure of cell membranes |
US5084269A (en) * | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
NZ222907A (en) * | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
CH681427A5 (es) * | 1987-07-01 | 1993-03-31 | Zambon Spa | |
JP2643217B2 (ja) * | 1988-01-22 | 1997-08-20 | エーザイ株式会社 | 脂溶性物質水性液 |
US5124151A (en) * | 1990-08-07 | 1992-06-23 | Mediventures Inc. | Drug delivery by injection with thermo-irreversible gels |
US5143731A (en) * | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
US5505877A (en) * | 1991-10-15 | 1996-04-09 | Krivohlavek; Dennis | Making multiple phase emulsion or gel |
DE4201527A1 (de) * | 1992-01-21 | 1993-07-22 | Knoll Ag | Lecithinhaltige loesungen mit levemopamil |
US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
US5660854A (en) * | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
-
1993
- 1993-09-08 SI SI9300468A patent/SI9300468A/sl unknown
- 1993-10-05 RU RU94033520/14A patent/RU94033520A/ru unknown
- 1993-10-05 CA CA002125784A patent/CA2125784A1/en not_active Abandoned
- 1993-10-05 AT AT93921914T patent/ATE180976T1/de not_active IP Right Cessation
- 1993-10-05 ES ES93921914T patent/ES2133413T3/es not_active Expired - Lifetime
- 1993-10-05 JP JP6509578A patent/JP2613750B2/ja not_active Expired - Fee Related
- 1993-10-05 EP EP93921914A patent/EP0620740B1/en not_active Expired - Lifetime
- 1993-10-05 NZ NZ256413A patent/NZ256413A/en unknown
- 1993-10-05 DE DE69325256T patent/DE69325256T2/de not_active Expired - Fee Related
- 1993-10-05 AU AU51110/93A patent/AU672441B2/en not_active Ceased
- 1993-10-05 WO PCT/EP1993/002711 patent/WO1994008623A1/en active IP Right Grant
- 1993-10-06 IL IL107207A patent/IL107207A0/xx unknown
- 1993-10-07 ZA ZA937459A patent/ZA937459B/xx unknown
- 1993-10-07 MX MX9306239A patent/MX9306239A/es unknown
- 1993-10-13 LV LV931150A patent/LV10180A/xx unknown
- 1993-10-13 IS IS4083A patent/IS4083A/is unknown
- 1993-10-13 CN CN93119112A patent/CN1090509A/zh active Pending
- 1993-10-13 UY UY23665A patent/UY23665A1/es unknown
-
1996
- 1996-08-22 US US08/701,274 patent/US5863549A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
LV10180A (lv) | 1994-10-20 |
AU5111093A (en) | 1994-05-09 |
EP0620740B1 (en) | 1999-06-09 |
CN1090509A (zh) | 1994-08-10 |
CA2125784A1 (en) | 1994-04-28 |
IS4083A (is) | 1994-04-15 |
RU94033520A (ru) | 1996-11-10 |
JPH06511263A (ja) | 1994-12-15 |
AU672441B2 (en) | 1996-10-03 |
SI9300468A (en) | 1994-06-30 |
ATE180976T1 (de) | 1999-06-15 |
UY23665A1 (es) | 1994-04-06 |
US5863549A (en) | 1999-01-26 |
DE69325256D1 (de) | 1999-07-15 |
JP2613750B2 (ja) | 1997-05-28 |
NZ256413A (en) | 1996-07-26 |
ZA937459B (en) | 1994-04-14 |
WO1994008623A1 (en) | 1994-04-28 |
DE69325256T2 (de) | 1999-12-16 |
EP0620740A1 (en) | 1994-10-26 |
MX9306239A (es) | 1994-06-30 |
ES2133413T3 (es) | 1999-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL107207A0 (en) | Sustained release pharmaceutical compositions | |
EP0761173A3 (en) | Needle for the administration of therapeutic solutions in the subarachnoid space | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
HUP0000558A3 (en) | Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases | |
HK1029925A1 (en) | Cannabinol-11-oic acid derivatives useful as antiinflammatory agents and analgesics | |
EP0734723A4 (en) | THERAPEUTIC COMPOSITION USEFUL FOR TREATING HYPERPARATHYROIDIA OF A PATIENT ON ARTIFICIAL DIALYSIS | |
ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
SG47451A1 (en) | Implantable therapy system | |
AU5323396A (en) | Methods of treating inflammation and compositions therefor | |
DE69426530D1 (de) | Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz | |
HUP9900147A2 (hu) | Terápiás szerek és autoimmun betegségek kezelésére alkalmas gyógyszerkészítmények | |
GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
MY104521A (en) | Treatment of depression. | |
DE69816808D1 (de) | Somatostatin agoniste zur reduzierung von körpergewicht | |
CS22891A2 (en) | Application of benzylphosphonic acid's derivatives for treatment of virusinduced diseases | |
EP0343671A3 (en) | Pharmaceutical composition for the treatment of skin wounds | |
EP0904094A4 (en) | TREATMENT OF BONE DISEASES USING ADRENOMEDULLINE | |
HUT71838A (en) | Use of biologically active ureido derivatives useful in the treatment of lentivirus-induced disease for producing pharmaceutical compositions | |
EP0301449A3 (en) | Enantiomers of propafenone-containing therapeutic agents | |
AU2699195A (en) | Biotin compounds for targetting tumors and sites of infection | |
CA2237643A1 (en) | Therapeutic agent for acute hepatic failure | |
IL110888A0 (en) | Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative | |
HU9802142D0 (en) | Use of na+/h+ -ion-exchange inhibitors for producing pharmaceutical compositions for treating and profilacting diseases of the central nerve system | |
UA22223A (uk) | Спосіб лікуваhhя захворюваhь оргаhа зору | |
MX9605327A (es) | Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis. |